Abstract

Non-alcoholic fatty liver disease (NAFLD)is accompanied by typical inflammatory damage and cell death. As a pro-inflammatory form of cell death, pyroptosis participates in important pathological processes involved in NAFLD. Regulatory roles of both CCCTC-binding factor (CTCF) and dipeptidyl peptidase-4 (DPP4) have been reported in NAFLD, but it is still unclear whether the mechanism of action of gardenoside, a potential therapeutic for NAFLD, can be driven via these proteins. In this study, the direct interaction between CTCF and DPP4 was first confirmed by a dual-luciferase reporter assay system. Then, a cell model of NAFLD was established by induction with palmitic acid (PA) and lipopolysaccharide (LPS). A mouse NAFLD model was established, and the effect of gardenoside on both the cell and mouse models of NAFLD was also investigated. Increased lipid accumulation, NLRP3 inflammasome activation, and hepatocyte pyroptosis were recorded in NAFLD in vitro and in vivo. Gardenoside treatment effectively reduced the lipid accumulation, increased cell viability, reduced reactive oxygen species (ROS) generation, and attenuated pyroptosis and apoptosis in NAFLD in the in vitro and in vivo models. Alterations in these biological processes were evidenced by the decreased expression levels of several pro-pyroptotic markers including the NLR family, pyrin domain-containing 3 (NLRP3), apoptosis-related speckle-like protein (ASC), caspase-1 p20, Gasdermin D N-terminal domain (GSDMD-N), and IL-1β, along with simultaneously decreased CTCF and DPP4 levels. Importantly, CTCF silencing or DPP4 silencing exhibited effects similar to gardenoside treatment, while CTCF overexpression counteracted this trend, which indicated that CTCF might be a target responsible for gardenoside-induced alleviation of NAFLD, such therapeutic effects might be achieved through controlling the expression of the direct target of CTCF (DPP4) and several downstream molecules. In general, the current study provides a promising strategy for NAFLD treatment.

Highlights

  • Non-alcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome characterized by steatosis of liver parenchyma and excessive accumulation of lipid in hepatocytes

  • The results showed that compared with co-transfection with plasmids pCDH-CCCTC-binding factor (CTCF) and pGL3basic, or transfection with pGL3-dipeptidyl peptidase-4 (DPP4)-promoter alone, the cotransfection with plasmids pCDH-CTCF and pGL3-DPP4promoter-WT led to significantly increased relative luciferase activity (p < 0.01) (Figure 2B)

  • To explore the hepatoprotective mechanism of gardenoside and its influence on the regulation of inflammasome and pyroptosis in NAFLD, we preliminarily examined the influence of gradient concentrations of gardenoside on lipid accumulation and the expression of proteins involved in the stimulation of NLRP3 inflammasome and caspase-1-induced pyroptosis

Read more

Summary

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome characterized by steatosis of liver parenchyma and excessive accumulation of lipid in hepatocytes. As a form of pro-inflammatory cell death, pyroptosis participates in the damage process involved in NAFLD (Beier and Banales, 2018). Several studies reported that pyroptosis in NAFLD is mainly mediated by the caspase-1 classical pyroptosis pathway (Qiu et al, 2018; Wu et al, 2019). In this pathway, apoptosisrelated speckle-like protein (ASC), absent in melanoma 2 (AIM2), NLR family pyrin domain containing 3 (NLRP3), and other pattern recognition receptors (PRRs) combine with procaspase-1 to form high-molecular inflammasome. It was reported that hyperglycemia and reactive oxygen species (ROS) caused by diabetes result in abnormal activation of NLRP3 inflammasome (Mathew, 2018; Oguntibeju, 2019), which, in turn, promotes liver fibrosis, cirrhosis, liver cell apoptosis, and pyroptosis

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call